Kidney cancer: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• PD-1 21
• PD-L1 11
• VEGF 10
• mTOR 1
• AKT 0
• VHL 6
• PI3K 0
• PSMA 10
• STAT3 0
• BAP1 1
• TP53 0
• JAK 0
• CTLA-4 4
• STING 1
• ALK 1
• EGFR 3
• TFEB 0
• ERK 0
• MYC 0
• HIF-1 0
• YAP 0
• AMPK 0
• CTNNB1 0
• MET 2
• B7-H3 2
• MAPK 0
• PPAR 0
• FGFR 1
• GLP-1 0
• GPC3 3
• HER2 2
• IL-6 0
• MMP-9 0
• PARP 1
• AXL 1
• BCL-2 0
• EZH2 0
• IDH 1
• NTRK 0
• PTEN 0
• BRAF 1
• CD19 1
• CDKN2A 0
• JNK 0
• KRAS 1
• LAG-3 0
• METTL3 1
• NLRP3 0
• NRF2 0
• PKM2 0
• ROS1 0
• TNF 0
• APOE 0
• BRCA1 0
• BRCA2 0
• BRD4 0
• CD20 0
• CDK4/6 0
• DPP-4 0
• FOXP3 0

EU-13 is a filter, not a ranking: it only narrows the list.

18 of 18+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Suspended

  Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC

  NCT06860386· H. Lee Moffitt Cancer Center and Research Institute· Updated 6 Mar 2026

  “Funding unavailable”Registry text, quoted unchanged. Source

• Terminated

  Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery

  NCT04370509· University of California, San Francisco· Updated 19 Nov 2025

  “Collaborating sponsor decision”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)

  NCT07489495· Merck Sharp & Dohme LLC· Source

• Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

  NCT07049926· Merck Sharp & Dohme LLC· Source

• Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

  NCT03793166· National Cancer Institute (NCI)· Source

• A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

  NCT04195750· Merck Sharp & Dohme LLC· Source

• Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)

  NCT02853331· Merck Sharp & Dohme LLC· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 37
• Organoids 4
• Mendelian Randomization Analysis 22
• CRISPR-Cas Systems 8
• Gene Expression Profiling 97
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 6
• Exome Sequencing 10
• Proteomics 25
• Metabolomics 12
• Mass Spectrometry 3
• Flow Cytometry 11
• Immunohistochemistry 95
• Liquid Biopsy 6
• Circulating Tumor DNA 8
• Xenograft Model Antitumor Assays 76
• Positron-Emission Tomography 13
• Magnetic Resonance Imaging 60
• Machine Learning 70
• Deep Learning 36
• Cohort Studies 67
• Genome-Wide Association Study 19

• Integrated single-cell and bulk transcriptomic analyses reveal ferro-aging-related molecular characteristics and immunological heterogeneity in renal cell carcinoma.

  PLoS One, Nov 2026

• TP53 shapes tumour-specific immune phenotypes across breast, colorectal and kidney human cancers.

  J Mol Med (Berl), Nov 2026

• Geometry based gene-expression signatures detect cancer treatment responders in clinical trials.

  BMC Cancer, Nov 2026

• PANoptosis-Related Molecular Subtyping and a Subtype-Derived Prognostic Signature for Survival Prediction in Clear Cell Renal Cell Carcinoma.

  Technol Cancer Res Treat, Oct 2026

• Integrative Molecular Profiling and Single-Cell Characterization of LHFPL5 Reveal Cancer-Specific Regulatory Features in Clear Cell Renal Cell Carcinoma and Lung Adenocarcinoma.

  Medicina (Kaunas), Oct 2026

• Identification and Clinical Significance of Differentially Expressed Genes in the Tumour Microenvironment of Clear Cell Renal Cell Carcinoma.

  J Coll Physicians Surg Pak, Oct 2026

• Integrative network toxicology and transcriptomic analyses identify DCP1B and HAS2 as key prognostic biomarkers in formaldehyde-associated Wilms tumor.

  J Int Med Res, Sept 2026

• Molecular underpinnings of metastatic small renal masses.

  JCI Insight, Sept 2026

• A mast cell-associated apoptosis-related transcriptomic signature in clear cell renal cell carcinoma and in vitro characterization of YBX3.

  Front Immunol, Sept 2026

• Multi-Omics Integration Identifies a Five-Gene Metabolic Signature With Experimental Validation in Clear Cell Renal Cell Carcinoma.

  Cancer Rep (Hoboken), Sept 2026

See which targets of this disease your abstract mentions, and go to the people working on them.